tallózása szerző szerint "Shousha S"

A találatok rendezése: Rendezés: Találatok:

  • Characterisation of male breast cancer: a descriptive biomarker study from a large patient series 
    Humphries MP; Sundara Rajan S; Honarpisheh H; Cserni, Gábor; Dent J; Fulford L; Jordan LB; Jones JL; Kanthan R; Litwiniuk M; Di Benedetto A; Mottolese M; Provenzano E; Shousha S; Stephens M; Kulka, Janina; Ellis IO; Titloye AN; Hanby AM; Shaaban AM; Speirs V (2017)
    Male breast cancer (MBC) is rare. We assembled 446 MBCs on tissue microarrays and assessed clinicopathological information, together with data from 15 published studies, totalling 1984 cases. By immunohistochemistry we ...
  • Enhancer mapping uncovers phenotypic heterogeneity and evolution in patients with luminal breast cancer 
    Patten DK; Corleone G; Győrffy, Balázs; Perone Y; Slaven N; Barozzi I; Erdős, Edina; Saiakhova A; Goddard K; Vingiani A; Shousha S; Pongor, Lőrinc; Hadjiminas DJ; Schiavon G; Barry P; Palmieri C; Coombes RC; Scacheri P; Pruneri G; Magnani L (2018)
    The degree of intrinsic and interpatient phenotypic heterogeneity and its role in tumor evolution is poorly understood. Phenotypic drifts can be transmitted via inheritable transcriptional programs. Cell-type specific ...
  • Expression of CDK7, cyclin H and MAT1 is elevated in breast cancer and is prognostic in estrogen receptor-positive breast cancer 
    Patel H; Abduljabbar R; Lai CF; Periyasamy M; Harrod A; Gemma C; Steel J; Patel N; Busonero C; Jerjees D; Remenyi J; Smith S; Gomm JJ; Magnani L; Győrffy, Balázs; Jones JL; Fuller-Pace FV; Shousha S; Buluwela L; Rakha EA; Ellis IO; Coombes RC; Ali S (2016)
    PURPOSE: CDK-activation kinase (CAK) is required for the regulation of the cell-cycle and is a trimeric complex consisting of Cyclin Dependent Kinase 7 (CDK7), Cyclin H and the accessory protein, MAT1. CDK7 also plays a ...
  • The pioneer factor PBX1 is a novel driver of metastatic progression in ERalpha-positive breast cancer 
    Magnani L; Patten DK; Nguyen VT; Hong SP; Steel JH; Patel N; Lombardo Y; Faronato M; Gomes AR; Woodley L; Page K; Guttery D; Primrose L; Fernandez Garcia D; Shaw J; Viola P; Green A; Nolan N; Ellis IO; Rakha EA; Shousha S; Lam EW; Győrffy, Balázs; Lupien M; Coombes RC (2015)
    Over 30% of ERalpha breast cancer patients develop relapses and progress to metastatic disease despite treatment with endocrine therapies. The pioneer factor PBX1 translates epigenetic cues and mediates estrogen induced ...